142 related articles for article (PubMed ID: 31656055)
1. Using GRADE methodology to assess innovation of new medicinal products in Italy.
Fortinguerra F; Tafuri G; Trotta F; Addis A
Br J Clin Pharmacol; 2020 Jan; 86(1):93-105. PubMed ID: 31656055
[TBL] [Abstract][Full Text] [Related]
2. The Assessment of the Innovativeness of a New Medicine in Italy.
Fortinguerra F; Perna S; Marini R; Dell'Utri A; Trapanese M; Trotta F;
Front Med (Lausanne); 2021; 8():793640. PubMed ID: 34957163
[No Abstract] [Full Text] [Related]
3. [Innovative medicinal products: the new criteria of the Italian Medicines Agency.].
Mammarella F; Tafuri G
Recenti Prog Med; 2018 May; 109(5):261-262. PubMed ID: 29771247
[TBL] [Abstract][Full Text] [Related]
4. Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system.
Galeone C; Bruzzi P; Jommi C
BMJ Open; 2021 Jan; 11(1):e041259. PubMed ID: 33441356
[TBL] [Abstract][Full Text] [Related]
5. [EMA approval procedures and assessment of innovation by AIFA: a cross sectional analysis.].
Lasala R
Recenti Prog Med; 2021 Apr; 112(4):273-284. PubMed ID: 33877088
[TBL] [Abstract][Full Text] [Related]
6. Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies.
Xoxi E; Di Bidino R; Leone S; Aiello A; Prada M
Front Med Technol; 2022; 4():917151. PubMed ID: 36134249
[TBL] [Abstract][Full Text] [Related]
7. The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy.
Xoxi E; Facey KM; Cicchetti A
Front Pharmacol; 2021; 12():699466. PubMed ID: 34456724
[TBL] [Abstract][Full Text] [Related]
8. The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency.
Jommi C; Galeone C
Pharmacoecon Open; 2023 May; 7(3):373-381. PubMed ID: 36763319
[TBL] [Abstract][Full Text] [Related]
9. Do France, Germany, and Italy agree on the added therapeutic value of medicines?
Casilli G; Lidonnici D; Jommi C; De Nigris M; Genazzani AA
Int J Technol Assess Health Care; 2023 Aug; 39(1):e54. PubMed ID: 37580971
[TBL] [Abstract][Full Text] [Related]
10. Skip pattern approach toward the early access of innovative anticancer drugs.
Apolone G; Ardizzoni A; Biondi A; Bortolami A; Cardone C; Ciniselli CM; Conte P; Crippa C; de Braud F; Duca M; Gori S; Gritti G; Inno A; Luksch R; Lussana F; Maio M; Pasello G; Perrone F; Rambaldi A; Rossi G; Signorelli D; Soverini G; Valente M; Verderio P; Buzzetti G
ESMO Open; 2021 Aug; 6(4):100227. PubMed ID: 34352703
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines - a case study of oncology drugs.
Gargano LP; Alvares-Teodoro J; de A Acurcio F; Guerra AA
Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; ():1-10. PubMed ID: 38859799
[TBL] [Abstract][Full Text] [Related]
12. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
[TBL] [Abstract][Full Text] [Related]
13. MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY.
Montilla S; Xoxi E; Russo P; Cicchetti A; Pani L
Int J Technol Assess Health Care; 2015 Jan; 31(4):210-3. PubMed ID: 26646859
[TBL] [Abstract][Full Text] [Related]
14. Do patients value a hospital's innovativeness reputation? A multi-method approach to assess the relative importance of innovativeness reputation in patients' hospital choice.
Gurtner S; Hietschold N; Vaquero Martín M
Health Serv Manage Res; 2018 Aug; 31(3):138-153. PubMed ID: 29277121
[TBL] [Abstract][Full Text] [Related]
15. Horizon Scanning for pharmaceuticals and effective health care programming: 2 years' experience at the Italian Medicines Agency.
Ivanovic J; Capone G; Raffaelli L; Pantò V; Marangi M
Drug Discov Today; 2021 Feb; 26(2):569-576. PubMed ID: 33220432
[TBL] [Abstract][Full Text] [Related]
16. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
[TBL] [Abstract][Full Text] [Related]
17. Drug Prescriptions in the Outpatient Management of COVID-19: Evidence-Based Recommendations Versus Real Practice.
Belleudi V; Finocchietti M; Fortinguerra F; Di Filippo A; Trotta F; Davoli M; Addis A
Front Pharmacol; 2022; 13():825479. PubMed ID: 35401220
[No Abstract] [Full Text] [Related]
18. Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience.
Salvo I; Landoni G; Mucchetti M; Cabrini L; Pani L
Paediatr Anaesth; 2014 Jun; 24(6):625-31. PubMed ID: 24796404
[TBL] [Abstract][Full Text] [Related]
19. Innovativeness as an emergent property: a new alignment of comparative and experimental research on animal innovation.
Griffin AS
Philos Trans R Soc Lond B Biol Sci; 2016 Mar; 371(1690):. PubMed ID: 26926287
[TBL] [Abstract][Full Text] [Related]
20. [Biosimilars: Italian Medicines Agency takes position.].
Addis A
Recenti Prog Med; 2018 Apr; 109(4):214-215. PubMed ID: 29689035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
